Shareholders in Regeneus have oversubscribed for its SPP by 10%, raising a further $300,000 to add to the $3,000,000. This is in addition to the earlier $3,000,000 placement to institutional and sophisticated investors. Funds raised will accelerate development of its cancer vaccines as well as off-the-shelf stem cell therapy for human osteoarthritis.
Shareholders in Regeneus have oversubscribed for its SPP by 10%,...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
